|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||36.54 - 37.08|
|52 Week Range||30.90 - 37.37|
|PE Ratio (TTM)||22.74|
|Forward Dividend & Yield||1.36 (3.68%)|
|1y Target Est||N/A|
The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent. Remicade generated U.S. sales of $4.8 billion for J&J in 2016 but it faces increased competition from cheaper "biosimilar" copycats, including Pfizer's version, which is sold in the United States under the name Inflectra.
A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed a ruling by a U.S. administrative court that a J&J patent covering the active ingredient in Remicade was invalid because its concepts were covered in a prior J&J patent.
Johnson & Johnson’s patent on its top-selling arthritis drug Remicade is invalid, a U.S. appeals court ruled Tuesday in a defeat to the drugmaker that just last week lost a patent on another blockbuster ...
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.